Schizophrenia

Details Schizophrenia Schizophrenia

1993-11-19

1996-05-14

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

A61K 3120

Patent

active

055168000

ABSTRACT:
The negative symptoms of schizophrenia and/or low cell membrane levels of EFAs may be treated with a combination of arachidonic acid and docosahexaenoic acid.

REFERENCES:
patent: 4526902 (1985-07-01), Rubin
patent: 4588721 (1986-05-01), Mahan
patent: 4882345 (1989-11-01), Gueremy et al.
patent: 4882352 (1989-11-01), Horn
patent: 4977187 (1990-12-01), Horrobin
patent: 5070101 (1991-12-01), Kaminski
patent: 5151419 (1992-09-01), Perenyi et al.
Neuroscience and Biobehavioral Reviews vol. 16, pp. 193-205, 1992 Wainwright "Do Essential Fatty Acids Play a Role in Brain and Behavioral Development?".
Biochemical Pharmacology, vol. 44, No. 2, pp. 317-323, 1992 Fischer et al "Schizophrenic Patients Treated with High Dose Phenothiazine or Thioxanthene Become Deficient in Polyunsaturated Fatty Acids in Their Thrombocytes".
Stedman's Medical Dictionary, 25th Edition, p. 1390, 1989.
Van Kammen et al, Medline Abstract #89372545 of Ann. N.Y. Acad. Sci, 1989, 559 (411-23), Polyunsaturated Fatty Acids, Prostaglandins, and Schizophrenia.
Maruha, K. K., WPIDS Abstract #94-128761 of JP06072864, 1984, Antipsychotic Agents-Contain Doca Sahexamenoic Acid.
Lehninger Albert, Biochemistry Second Edition, 1975, pp. 281-282.

Affiliated with

Also associated with

Rating

Schizophrenia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Schizophrenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Schizophrenia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1895984